Home › Forums › General DCA Discussion › CPI-613
This topic contains 2 replies, has 2 voices, and was last updated by Dan52 5 years, 1 month ago.
CPI-613 is a new anti-cancer agent that targets mitochondrial metabolism in the cancer cells. See this article on PubMed:
The mechanism of action sounds similar to DCA. But… I can be completely wrong as am not an expert. I don’t have any medical training.
I found several ongoing clinical trials that test CPI-613:
Any comments? Do you agree that it sounds similar to DCA?
I’m not a doctor but I agree. Based on the abstract, CPI-613 like DCA seems to inhibit pyruvate dehydrogenase kinase (PDK) inactivating the glycolysis.
Just to add that I can’t find in CPI-613 (maybe reported in next studies?) an important aspect of DCA: it can inhibit angiogenesis (http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2012198a.html).
You must be logged in to reply to this topic.
Comments are closed.